TITLE

Hepatitis A vaccine: Is it being used to best advantage?

AUTHOR(S)
Scheifele, David W.; Ochnio, Jan
PUB. DATE
July 2002
SOURCE
CMAJ: Canadian Medical Association Journal;7/9/2002, Vol. 167 Issue 1, p44
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Questions whether the Hepatitis A vaccine is being used to the best advantage. How the infection has caused substantial morbidity in children of school age and adults; Symptoms, which include prolonged nausea, anorexia and weakness; How Hepatitis A virus vaccines are remarkably immunogenic, requiring only a single dose to induce protection and one later dose to sustain for many years.
ACCESSION #
6982582

 

Related Articles

  • The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta-analysis. Fisman, David N.; Agrawal, Deepak; Leder, Karin // Clinical Infectious Diseases;12/1/2002, Vol. 35 Issue 11, p1368 

    Hepatitis B vaccine is a key tool for the prevention of hepatitis B infection. Age-associated changes in immune function may contribute to decreased vaccine efficacy in older individuals, although research related to this topic has yielded contradictory findings. We performed a meta-analysis of...

  • A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kong, N. C. T.; Beran, J.; Kee, S. A.; Miguel, J. L.; Sánchez, C.; Bayas, J.-M.; Vilella, A.; Calbo-Torrecillas, F.; López de Novales, E.; Srinivasa, K.; Stoffel, M.; Hoet, B. // Kidney International;Apr2008, Vol. 73 Issue 7, p856 

    Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody...

  • CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Angel, Jonathan B.; Cooper, Curtis L.; Clinch, Jennifer; Young, Charlene D.; Chenier, Andreane; Parato, Karl G.; Lautru, Michael; Davis, Heather; Cameron, Donald W. // Journal of Immune Based Therapies & Vaccines;2008, Vol. 6, Special section p1 

    Background: Lack of adequate adjuvancy is a possible explanation for lack of vaccine immunogenecity. Immunostimulatory CpGs are potent vaccine adjuvants and may be an important component of the development vaccines, particularly those for which a cellular immune response is required for...

  • Failure of Hepatitis B Immunization in Liver Transplant Recipients: Results of a Prospective Trial. Carey, William; Pimentel, Ronnie; Westveer, Mary Kay; Vogt, David; Broughan, Thomas // American Journal of Gastroenterology;Dec1990, Vol. 85 Issue 12, p1590 

    Twenty patients with advanced liver disease, in need of transplantation, were given three injections of 20 µg and three injections of 40 µg hepatitis B vaccine to see if an antibody response could be obtained. Only 20% of patients developed measurable anti-HBs. One who failed to develop...

  • Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection. Saygun, Onur; Eyigün, Can Polat; Avci, Ismail Yaşar; Kisa, Üçler; Pahsa, Alaaddin // Turkish Journal of Medical Sciences;2009, Vol. 39 Issue 2, p173 

    Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated....

  • A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Bogdanos, Dimitrios-Petrou; Smith, Heather; Yun Ma; Baum, Harold; Mieli-Vergani, Giorgina; Vergani, Diego // Clinical & Developmental Immunology;Sep2005, Vol. 12 Issue 3, p217 

    On the basis of the reported association between hepatitis B vaccination (HBvacc) and autoimmune demyelinating complications such as multiple sclerosis (MS), we have looked for aminoacid similarities between the small hepatitis B virus surface antigen (SHBsAg), and the MS-autoantigens myelin...

  • No scientific justification to suspend hepatitis B immunization.  // Public Health Reports;Nov/Dec98, Vol. 113 Issue 6, p487 

    Discusses the issue that hepatitis B immunization might be linked to the development of demyelinating disease. Scientific evidence on whether HB vaccine can cause multiple sclerosis (MS) according to the World Health Organization (WHO); Concern of WHO over France's decision to suspend routine...

  • Breakthrough Hepatitis B Virus (HBV) Infection From Mother-to-Infant Transmission Is the Key Problem Hindering HBV Eradication. Su, Wei-Ju; Chen, Huey-Ling; Chang, Mei-Hwei // Journal of Infectious Diseases;Sep2013, Vol. 208 Issue 6, p1036 

    A letter to the editor is presented related to a study, which illustrates that infants, who were born to mothers with positive and negative hepatitis B virus (HBV) e-antigen (HBeAg), developed acute hepatitis in Taiwan and suggests decline in HBV immunoglobulin vaccine potential.

  • Hepatitis B vaccine efficacy in HCV vertical infected infants. Aniszewska, Malgorzata; Kowalik-Mikolajewska, Barbara; Pokorska-Lis, Maria // Retrovirology;2008 Supplement 1, Vol. 5, Special section p1 

    Aim The aim of the study was to evaluate the immunogenicity of hepatitis B vaccine after primary immunization in children vertically infected with HCV. Patients and methods 105 infants born to HCV infected mothers were vaccinated against hepatitis B virus (recombinant vaccine, 10 µg, 0-1-6...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics